Skip to content
ANAVEX
ANAVEX
  • HOME
  • ABOUT US
  • NEWS
  • PIPELINE
  • INVESTORS
    • Events
    • Share Data
    • Analyst Coverage
    • Code of Conduct
    • Investor Material
  • JOIN US
Search
  • HOME
  • ABOUT US
  • NEWS
  • PIPELINE
  • INVESTORS
    • Events
    • Share Data
    • Analyst Coverage
    • Code of Conduct
    • Investor Material
  • JOIN US
View allAlzheimer's DiseaseAnavex2-73EventsNews ReleasesPDDPIPELINEPressRett Syndrome
Feb112021

Anavex Life Sciences Reports Fiscal 2021 First Quarter Financial Results And Business Outlook  

February 11, 2021
Feb82021

Anavex Life Sciences to Announce Fiscal 2021 First Quarter Financial Results and Business Outlook on Thursday, February 11, 2021

February 8, 2021
Jan62021

Anavex Life Sciences to Present at the H.C. Wainwright Virtual BioConnect Conference

January 6, 2021
Dec282020

Anavex Life Sciences Reports Fiscal 2020 Year End Financial Results And Clinical Program Updates

December 28, 2020
Dec222020

Anavex Life Sciences to Announce Fiscal 2020 Year End Financial Results December 28th, 2020

December 22, 2020
Dec212020

Anavex Life Sciences Announces Webinar on Rett Syndrome and ANAVEX®2-73 (Blarcamesine) Phase 2 Data hosted by Ladenburg Thalmann & Co.

December 21, 2020
Dec152020

Anavex Life Sciences Announces ANAVEX®2-73 (Blarcamesine) Meets Primary and Secondary Endpoints in Placebo-Controlled U.S. Phase 2 Clinical Trial for the Treatment of Adult Patients with Rett Syndrome

December 15, 2020
Sep102020

Anavex Life Sciences Announces Completion of ANAVEX®2-73 (blarcamesine) U.S. Phase 2 Rett Syndrome Clinical Trial

September 10, 2020

ANAVEX® is a trademark of Anavex®Life Sciences Corp. - 2019 All Rights Reserved

Go to Top